Home › Diffuse Large B-Cell Lymphoma › Maryland
Diffuse Large B-Cell Lymphoma clinical trials in Maryland
13 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Maryland.
Cities in Maryland
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06649812Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT03223610A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- American Oncology Partners of Maryland Pa, Bethesda
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06091865A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- American Oncology Partners, P.A. ( Site 0185), Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04002947Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
- The Center for Cancer and Blood Disorders, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06500273Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 25, 2026 · NCT05389423Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institute of Health, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 2, 2026 · NCT05633615From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.